Abstract：Succinic semialdehyde dehydrogenase (SSADH) deficiency is a rare autosomal recessive disorder. This paper reports three cases of SSADH deficiency in infants. The infants developed the symptoms including developmental delay, intellectual disability, hypotonia, hyporeflexia and seizures. The electroencephalogram (EEG) showed background slowing and focal spike discharges in all of 3 patients. Head magnetic resonance imaging (MRI) demonstrated abnormalities in 2 patients, including basal ganglia damage and increased T2-weighted signal in bilateral cerebral peduncles. Urinary organic acid analysis with gas chromatography-mass spectrometry (GC-MS) revealed increased levels of 4-hydroxybutyrate (GHB) in 3 patients. SSADH deficiency was definitely diagnosed based on the clinical manifestations and the results of urinary organic acid analysis in the 3 children. It was concluded that early urine organic acid analysis is essential for children presenting with mental retardation, neuropsychiatric disturbance or epilepsy of unknown etiology.
［1］Jakobs C, Bojasch M, Monch E, Rating D, Siemes H, Hanefeld F. Urinary excretion of gamma-hydroxybutyric acid in a patient with neurological abnormalities. The probability of a new inborn error of metabolism［J］. Clin Chim Acta, 1981, 111(2-3):169-178.
［2］Pearl PL, Gibson KM, Cortez MA, Wu Y, Carter Snead O 3rd, Knerr I, et al. Succinic semialdehyde dehydrogenase deficiency: lessons from mice and men［J］. J Inherit Metab Dis, 2009, 32(3): 343-352.
［5］Trettel F, Malaspina P, Jodice C, Novelletto A, Slaughter CA, Caudle DL, et al. Human succinic semialdehyde dehydrogenase. Molecular cloning and chromosomal localization［J］. Adv Exp Med Biol, 1997, 414:253-260.
［6］Pearl PL, Gibson KM, Acosta MT, Vezina LG, Theodore WH, Rogawski MA, et al. Clinical spectrum of succinic semialdehyde dehydrogenase deficiency［J］. Neurology, 2003, 60(9): 1413-1417.
［7］Knerr I, Gibson KM, Murdoch G, Salomons GS, Jakobs C, Combs S, et al. Neuropathology in succinic semialdehyde dehydrogenase deficiency［J］. Pediatr Neurol, 2010, 42(4): 255-258.
［8］Pearl PL, Taylor JL, Trzcinski S, Sokohl A. The pediatric neurotransmitter disorders［J］. J Child Neurol, 2007, 22(5):606-616.
［9］Pearl PL,Capp PK, Novotny EJ, Gibson KM. Inherited disorders of neurotransmitters in children and adults［J］. Clin Biochem, 2005, 38(12):1051-1058.
［10］Rahbeeni Z, Ozand PT, Rashed M, Gascon GG, al Nasser M, al Odaib A, et al. 4-Hydroxybutyric aciduria［J］. Brain Dev, 1994,16(suppl):64-71.
［11］Lee WT, Weng WC, Peng SF, Tzen KY. Neuroimaging findings in children with paediatric neurotransmitter diseases［J］. J Inherit Metab Dis, 2009, 32(3):361-370.
［12］Pearl PL, Vezina LG, Saneto RP, McCarter R, Molloy-Wells E, Heffron A, et al. Cerebral MRI abnormalities associated with vigabatrin therapy［J］. Epilepsia, 2009, 50(2):184-194.
［13］Leuzzi V, Di Sabato ML, Deodato F, Rizzo C, Boenzi S, Carducci C, et al. Vigabatrin improves paroxysmal dystonia in succinic semialdehyde dehydrogenase deficiency［J］. Neurology, 2007, 68(16):1320-1321.
